admed laboratory adopts QuantaMatrix dRAST solution in routine clinical use

• QuantaMatrix’s direct Rapid Antimicrobial Susceptibility Testing system (dRAST™) improves optimal prescription of antibiotics by two days compared to conventional methods
• This follows successful adoption of dRAST solution in routine clinical use in five clinical laboratories in Europe and Asia 

Paris, France and Seoul, South Korea, October 5, 2022 – QuantaMatrix, an in vitrodiagnostics company specializing in the discovery, development and commercialization of fully integrated solutions within the sepsis value chain, today announces that its dRAST™ solution has been adopted for routine clinical use by admed, a Swiss-based laboratory. This successful implementation is the result of a partnership between QuantaMatrix Europe, a fully owned affiliate of QuantaMatrix Inc., based in Paris (France) and Axonlab, one of the leading in vitro diagnostics solution providers in Europe. 

This is the sixth application of the dRAST solution, adding to a list of current users that includes Seoul National University Hospital, Chungnam National University Hospital, the Catholic University of Korea Seoul St. Mary’s Hospital, Konkuk University Medical Center and the Limbach Group. 

admed was created from the merger of three laboratories in the canton of Neuchâtel, Switzerland. As a recognized laboratory based at seven sites, it covers many areas of expertise, such as laboratory medicine, immunopathology and microbiology. Each year, the admed laboratory manages over 3,000 patients with suspected clinical sepsis. admed is committed to the patient’s well-being; providing quick, reliable and qualitative results. These values align well with QuantaMatrix’s mission and the dRAST solution, which has now been adopted at the admed laboratory in routine clinical use. 

“The implementation of dRAST in our laboratory will greatly simplify our management of positive blood cultures, at all times, while significantly reducing the time required to deliver antibiotic susceptibility test results,” said Dr. Antony Croxatto, director of the microbiology department at the admed laboratory. “Indeed, dRAST will enable us to provide same-day results if the blood cultures are positive and save 16 to 24 hours compared to conventional methods. Patients will more swiftly benefit from appropriate antibiotic therapy, potentially reducing the risks of complications and prolonged hospital stays. dRAST is perfectly in line with our objectives to improve our services for patients and clinicians.” 

“We are happy to announce this partnership with admed, a company with a wealth of experience and values that align with our own,” said Sunghoon Kwon, CEO of QuantaMatrix. “This is a great opportunity for QuantaMatrix to bring faster diagnoses to patients and create better sepsis care.” 

QuantaMatrix’s dRAST aims to help clinicians by providing optimal antibiotic treatments for sepsis patients. Its gram-negative and gram-positive antibiotic panels deliver fast results for a large variety of sepsis-causing bacteria. Sepsis is the body’s extreme response to a bacterial infection in the bloodstream. When this occurs, septic shock triggers a chain reaction through the body that leads to tissue damage, organ failure and, if left untreated, death. Globally, today, sepsis claims a life every 2.8 seconds. Statistically, sepsis is the number one cause of death in hospitals, with a 30-day mortality rate of 20 to 30 percent. The treatment of sepsis is a fight against time. Any delay in treatment reduces the survival rate of a patient by 7-9% per hour. The dRAST solution contains various innovative patents and a collection of over 30 million data points on bacteria growth to cut down diagnostic time from several days to as little as four hours.

About QuantaMatrix
QuantaMatrix Inc. is an in vitro diagnostics company specializing in the discovery, development and commercialization of fully-integrated solutions within the sepsis value chain. QuantaMatrix has successfully established a distribution network all over Europe. It continues to expand and is now addressing the Middle East and Africa. QuantaMatrix specializes in in vitro diagnostics using microbial diagnostics technology.

QuantaMatrix’s flagship product is its dRAST™ solution, a direct Rapid Antimicrobial Susceptibility Testing system, which is capable of finding the optimal antibiotic in four to six hours following a positive blood culture. The dRAST solution uses various patented technologies related to optics, microfluidic engineering and artificial intelligence. Compared to conventional methods, dRAST effectively shortens the time to results by two to three days.

The dRAST solution is available in Korea, Europe and the Middle East. QuantaMatrix has a distribution network spanning 26 countries in the EMEA region and continues to expand.QuantaMatrix is a public company listed on the Korean KOSDAQ market under #317690.

www.quantamatrix.com